Company Investors Technology Careers Updates Events Contact Team Founded by the team that discovered the generation of beneficial anti-angiogenic forms of VEGF All Teams Board Scientific Advisory Board Management Clinical Advisory Board Dr Catherine Beech Chief Executive Officer Professor David Bates Chief Scientific Officer Professor Steven Harper Medical Director Sunil Shah Chairman Dr Chris Torrance Chief Executive Officer, PhoreMost Ltd Dr John Kurek Biotechnology Investment Manager, Uniseed Dr Andrew Naylor CEO, Nottingham Technology Ventures Ltd Dr Andy Baxter Discovery and Development Consultant, ProPharma Partners Ltd Dr Loic Lhuillier Chief Operating Officer Chris O'Connor Financial Controller Dr Kenneth McKechnie Head of Biology Professor Lucy Donaldson Founding scientist Dr Kenton Zavitz SAB Chairman Dr Joe Hopcraft Brand Lead for Hemophilia, Endocrine Care and Treatment, Pfizer Professor Andrew Dick Professor of Ophthalmology, University of Bristol Professor Lloyd Paul Aiello Professor of Ophthalmology at Harvard Medical School Professor Peter Campochiaro Professor of Ophthalmology and Neuroscience at the Johns Hopkins Wilmer Eye Institute Professor Usha Chakravarthy Institute for Ophthalmology and Vision Science, Queen’s University, Belfast Professor Robyn Guymer Professor of Ophthalmology at Melbourne University Dr Sam Fazeli Senior analyst and the EMEA head of Bloomberg Intelligence Get in touch with us Work with us to improve the treatment of patients with retinal vascular diseases CONTACT US Who we are Exonate is a biopharmaceutical company focused on the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. Alternative mRNA splicing is modulated in disease states resulting in pathological blood vessel formation (angiogenesis) This is a key driver of disease progression in some ophthalmic conditions and cancers. Follow us on Social Media Useful links Career opportunities Technology Investors Contact Copyright © 2021 Exonate Privacy policy Designed and built by Onespacemedia

Company Investors Technology Careers Updates Events Contact Investors Exonate is funded through non-clinical development Remarkable Opportunity to Invest mRNA splicing-related diseases constitute a large and growing market LEARN MORE Who we are Exonate is a biopharmaceutical company focused on the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. Alternative mRNA splicing is modulated in disease states resulting in pathological blood vessel formation (angiogenesis) This is a key driver of disease progression in some ophthalmic conditions and cancers. Follow us on Social Media Useful links Career opportunities Technology Investors Contact Copyright © 2021 Exonate Privacy policy Designed and built by Onespacemedia